Rohan Vaidya, DO | |
6535 Nemours Pkwy, Orlando, FL 32827-7884 | |
(407) 567-4000 | |
Not Available |
Full Name | Rohan Vaidya |
---|---|
Gender | Male |
Speciality | Psychiatry & Neurology - Neurology With Special Qualifications In Child Neurology |
Location | 6535 Nemours Pkwy, Orlando, Florida |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053840967 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084N0402X | Psychiatry & Neurology - Neurology With Special Qualifications In Child Neurology | OS19873 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Rohan Vaidya, DO 13220 Granger Ave, Orlando, FL 32827-3856 Ph: (408) 806-7655 | Rohan Vaidya, DO 6535 Nemours Pkwy, Orlando, FL 32827-7884 Ph: (407) 567-4000 |
News Archive
Abbott Pharmaceuticals has announced the withdrawal of weight loss drug Meridia from shelves in the United States and urged patients to stop taking it after regulators questioned its safety. The withdrawal happened last Friday in the US. In January, Meridia sales were suspended in Europe.
The ATS congratulates the FDA on its important, but belated action, to remove flavored e-cigarette products from the U.S. market. Since e-cigarette products first emerged in the U.S., the American Thoracic Society has consistently called on FDA to aggressively regulate e-cigarettes and has repeatedly urged the FDA to ban flavored e-cigarettes from the U.S. market.
In analysis that included more than 9 million Department of Defense nonactive and active duty personnel, the rates of both community-onset and hospital-onset methicillin-resistant Staphylococcus aureus (MRSA) bacteremia decreased from 2005 to 2010, while the proportion of community-onset skin and soft tissue infections due to MRSA has more recently declined, according to a study in the July 4 issue of JAMA.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.
› Verified 5 days ago
Dr. Manuel Ramon Mota-castillo, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5979 Vineland Rd Ste 109, Orlando, FL 32819 Phone: 407-270-7702 Fax: 407-270-7705 | |
Luis E Bello Espinosa, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 100 W Gore St Ste 600, Orlando, FL 32806 Phone: 321-841-3050 Fax: 321-843-3570 | |
Dr. Janette Torres-cruz, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 5201 Raymond St, Orlando, FL 32803 Phone: 407-518-5004 Fax: 407-599-1558 | |
Dr. Ricardo Bernal, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 8751 Commodity Cir, Suite 3, Orlando, FL 32819 Phone: 407-226-2777 | |
Anita Marie Fletcher, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 265 E Rollins St Fl 6, Orlando, FL 32804 Phone: 859-519-8673 | |
Ingrid Stringa, APRN Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2881 Delaney Ave, Orlando, FL 32806 Phone: 407-652-6000 | |
Marcia L Verduin, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 5201 Raymond St, Orlando, FL 32803 Phone: 407-629-1599 |